Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of BL-M07D1 versus physician's choice chemotherapy in HER2-expressing advanced biliary tract cancer after platinum failure
CTR20261975Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of BL-M07D1 in biliary cancer (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoint: Overall survival. Started Jul 2026; status: active.
02
Drugs
BL-M07D1
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20261975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261975.